Clinical Trial: A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185477) titled 'A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma' on Sept. 05.

Brief Summary: This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).

Study Start Date: Sept. 15

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma (RRMM)

Intervention: BIOLOGICAL: QLS32015

QLS32015 is a GPRC5D x CD3 bispecific an...